Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Mutual Antibody T cell Engagers (MATEs): A safe, flexible alternative to Chimeric Antigen Receptor T cell therapy for leukemia and lymphoma
EF 2018-19
Résumé
Chimeric Antigen Receptor (CAR) T cell therapy is a revolutionary treatment delivering complete response rates up to 90% for CD19+ B cell leukemias and lymphomas, yet problems with response durability and toxicity remain. CARs are engineered receptors expressed in T cells that contain an extracellular Antibody Domain (AD), targeting a known antigen, and an intracellular Signaling Domain (SD), which initiates proliferation, cytokine production, and cytotoxicity.
Despite impressive efficacy, CAR T cells exhibit unpredictable expansion, ranging from inadequate, which allows tumor escape, to excessive, resulting in life-threatening side effects including cytokine release syndrome and neurotoxicity.
To resolve this, our lab is developing a novel strategy called Mutual Antibody T cell Engagers (MATEs). The MATE strategy splits the CAR AD and SD into two separate proteins, utilizing a leucine zipper to connect them in a non-covalent fashion. In this way, the MATE behaves like a CAR only when the AD is present, providing physicians with exquisite control over T cell activity.
My research aims to test the activation, proliferation, and target cell cytotoxicity of T cells transduced to express the MATE SD (MATE T cells) in the presence of varying doses of the MATE AD. We expect these activities to increase with escalating doses of the AD, defining the dose-dependent relationship between it and MATE T cells.
In summary, the MATE strategy offers control not previously afforded by CAR T cell therapy, improving safety and flexibility. In future, this strategy could also be used to target several antigens simultaneously using multiple ADs and a single SD, thereby reducing the risk of tumor escape as seen with about one-third of patients after they receive CD19+ CAR T cell therapy.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
406370
Name
Banville Allyson
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Mutual Antibody T cell Engagers (MATEs): A safe, flexible alternative to Chimeric Antigen Receptor T cell therapy for leukemia and lymphoma
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antigens; Cancer; Car-T Cell; Flexibility; Immunotherapy; Leukemia; Lymphoma; Safety; Targeted
Abstract
Chimeric Antigen Receptor (CAR) T cell therapy is a revolutionary treatment delivering complete response rates up to 90% for CD19+ B cell leukemias and lymphomas, yet problems with response durability and toxicity remain. CARs are engineered receptors expressed in T cells that contain an extracellular Antibody Domain (AD), targeting a known antigen, and an intracellular Signaling Domain (SD), which initiates proliferation, cytokine production, and cytotoxicity.
Despite impressive efficacy, CAR T cells exhibit unpredictable expansion, ranging from inadequate, which allows tumor escape, to excessive, resulting in life-threatening side effects including cytokine release syndrome and neurotoxicity.
To resolve this, our lab is developing a novel strategy called Mutual Antibody T cell Engagers (MATEs). The MATE strategy splits the CAR AD and SD into two separate proteins, utilizing a leucine zipper to connect them in a non-covalent fashion. In this way, the MATE behaves like a CAR only when the AD is present, providing physicians with exquisite control over T cell activity.
My research aims to test the activation, proliferation, and target cell cytotoxicity of T cells transduced to express the MATE SD (MATE T cells) in the presence of varying doses of the MATE AD. We expect these activities to increase with escalating doses of the AD, defining the dose-dependent relationship between it and MATE T cells.
In summary, the MATE strategy offers control not previously afforded by CAR T cell therapy, improving safety and flexibility. In future, this strategy could also be used to target several antigens simultaneously using multiple ADs and a single SD, thereby reducing the risk of tumor escape as seen with about one-third of patients after they receive CD19+ CAR T cell therapy.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Banville, Allyson
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~